foto

S.C. Gouw MD PhD

Position
Medical Specialist
Main activities
Patient care, Research
Specialisation
Pediatrics, pediatric hematology
Focus of research

Genetic and environmental risk factors of inhibitor development in patients with severe haemophilia A

Immune tolerance induction in inhibitor patients with severe haemophilia A

Female carriers of haemophilia and Von Willebrand disease

Key publications
  • Gouw Samantha C., van der Bom Johanna G., Ljung Rolf, Escuriola Carmen, Cid Ana R., Claeyssens-Donadel Ségolène, van Geet Christel, Kenet Gili, Mäkipernaa Anne, Molinari Angelo Claudio, Muntean Wolfgang, Kobelt Rainer, Rivard George, Santagostino Elena, Thomas Angela, van den Berg H. Marijke, Altisent C., Auerswald G., Carcao M., Chalmers E., Chambost H., Cid A., Claeyssens S., Clausen N., Fischer K., van Geet Ch, Peerlinck K., Kenet G., Kobelt R., Kreuz W., Escuriola C., Kurnik K., Liesner R., Ljung R., Mäkipernaa A., Molinari A., Muntean W., Nolan B., Oldenburg J., Pérez Garrido R., Petrini P., Platokouki H., Rafowicz A., Rivard G., Santagostino E., Mancuso M. E., Thomas A., Williams M., van der Bom J. G., van den Berg H. M. Factor VIII products and inhibitor development in severe hemophilia A New England journal of medicine 2013;368 (3):231-239 [PubMed]
  • Gouw Samantha C., van den Berg H. Marijke, Oldenburg Johannes, Astermark Jan, de Groot Philip G., Margaglione Maurizio, Thompson Arthur R., van Heerde Waander, Boekhorst Jorien, Miller Connie H., le Cessie Saskia, van der Bom Johanna G. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis Blood 2012;119 (12):2922-2934 [PubMed]
  • Gouw Samantha C., van der Bom Johanna G., Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study Blood 2007;109 (11):4648-4654 [PubMed]
  • Gouw Samantha C., van der Bom Johanna G., Auerswald Günter, Ettinghausen Carmen Escuriola, Tedgård Ulf, van den Berg H. Marijke Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study Blood 2007;109 (11):4693-4697 [PubMed]
  • Gouw S. C., van den Berg H. M., le Cessie S., van der Bom J. G. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A Journal of thrombosis and haemostasis 2007;5 (7):1383-1390 [PubMed]
All Publications
Research programmes

Prof. C.J. Fijnvandraat PhD (Etiology of inhibitor development in hemophilia & Alloimunisation in Sickle Cell Disease)

Current research funding
  • Baxalta US Inc., a Delaware corporation
  • CSL Behring GmbH
  • EAHAD
  • NWO
  • Swedish Orphan Biovitrum BVBA/SPRL